Protagonist Therapeutics (PTGX) Projected to Post Quarterly Earnings on Friday

Protagonist Therapeutics (NASDAQ:PTGX) is expected to issue its Q4 2025 results before the market opens on Friday, February 20th. Analysts expect the company to announce earnings of ($0.53) per share for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, February 20, 2026 at 12:30 PM ET.

Protagonist Therapeutics Price Performance

Shares of PTGX stock opened at $81.93 on Friday. Protagonist Therapeutics has a 12-month low of $33.70 and a 12-month high of $96.54. The firm has a market capitalization of $5.12 billion, a price-to-earnings ratio of 132.15 and a beta of 2.26. The business has a 50 day simple moving average of $85.43 and a 200 day simple moving average of $74.47.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. JPMorgan Chase & Co. raised their target price on shares of Protagonist Therapeutics from $68.00 to $81.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Jefferies Financial Group increased their price objective on shares of Protagonist Therapeutics from $95.00 to $118.00 and gave the company a “buy” rating in a report on Monday, February 2nd. Truist Financial raised their price objective on shares of Protagonist Therapeutics from $88.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, January 5th. BTIG Research restated a “buy” rating and issued a $82.00 target price on shares of Protagonist Therapeutics in a research report on Tuesday, October 28th. Finally, HC Wainwright lifted their price target on Protagonist Therapeutics from $80.00 to $117.00 and gave the company a “buy” rating in a research report on Friday, January 30th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Protagonist Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $91.64.

Insider Activity

In other news, insider Arturo Md Molina sold 5,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $82.00, for a total value of $410,000.00. Following the transaction, the insider directly owned 84,115 shares of the company’s stock, valued at $6,897,430. This trade represents a 5.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director William D. Waddill sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $83.68, for a total transaction of $1,673,600.00. Following the completion of the sale, the director owned 7,825 shares of the company’s stock, valued at approximately $654,796. This trade represents a 71.88% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 185,167 shares of company stock valued at $15,405,639 over the last ninety days. Corporate insiders own 4.90% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of PTGX. Parkman Healthcare Partners LLC lifted its position in shares of Protagonist Therapeutics by 0.4% in the third quarter. Parkman Healthcare Partners LLC now owns 61,849 shares of the company’s stock worth $4,109,000 after purchasing an additional 253 shares in the last quarter. Guggenheim Capital LLC boosted its position in Protagonist Therapeutics by 1.6% during the second quarter. Guggenheim Capital LLC now owns 19,208 shares of the company’s stock valued at $1,062,000 after purchasing an additional 303 shares during the last quarter. Orion Porfolio Solutions LLC lifted its holdings in shares of Protagonist Therapeutics by 5.0% during the 3rd quarter. Orion Porfolio Solutions LLC now owns 6,928 shares of the company’s stock valued at $460,000 after buying an additional 328 shares during the last quarter. Franklin Resources Inc. grew its stake in shares of Protagonist Therapeutics by 0.4% in the 3rd quarter. Franklin Resources Inc. now owns 82,918 shares of the company’s stock valued at $5,508,000 after buying an additional 339 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Protagonist Therapeutics by 0.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,403 shares of the company’s stock valued at $1,810,000 after buying an additional 348 shares in the last quarter. 98.63% of the stock is owned by institutional investors and hedge funds.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.